Differences between active late aGVHD and active cGVHD between days 100 and 114 and patients at risk for future late aGVHD. Volcano plots showing significant markers that meet all 3 criteria of a P ≤ .05 (y-axis), ROC AUC of ≥0.60 (circle, ≥0.60; cross, <0.6), and effect ratio ≥1.3 or ≤0.75 (x-axis). The subfigures correspond to (A) active late aGVHD compared with patients that have no later cGVHD, (B) active late aGVHD compared with tolerant patients with no cGVHD and no previous aGVHD, (C) active cGVHD that occurred before day 114 compared with the cGVHD cohort (same as in Figure 2A) that will develop cGVHD after day 114. Cell population are identified by color, with dark blue representing B cells, orange myeloid populations, yellow NK cells, purple NK_reg cells, green T cells, light blue T_reg cells, and dark red plasma cytokines. We note the following clinical variables were modeled as confounding factors in the logistic regression model: (1) prophylaxis or treatment with either alemtuzumab or ATG, (2) prophylaxis or treatment with rituximab, (3) recipient age, (4) the use of a peripheral blood donor product or not, and (5) whether the donor was HLA-identical or not.